Masimo Corporation (MASI) on Decifer

Decifer ranks MASI number 143 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 18% and those returns have been improving.
• Revenue is expected to grow about 8% a year, profits grew 51% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong returns near 18% with profits up 51% and momentum of 20 out of 35 are attractive, but revenue expected to grow only about 8% and no worldview role cap the case.

The current read

The evidence on MASI lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Masimo Corporation operates in medical - devices. That places it inside the Healthcare, Biotech & Devices story.

Read the full MASI research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.